Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114698 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01114698 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 12 participants.
The verdict
NCT01114698, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
Interventions
- DRUG Placebo
- DRUG Venlafaxine XR
- DRUG JNJ26489112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114698
The ClinicalTrials.gov registry entry for NCT01114698 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01114698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114698 about?
NCT01114698 is a clinical study titled "A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder". The purpose of this study is to evaluate the effectiveness and safety of JNJ26489112 compared with an active control (Venlafaxine XR) and placebo in patients with Treatment-Resistant Major Depressive Disorder.
What is the current status of trial NCT01114698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01114698?
The interventions under investigation include: Placebo (DRUG), Venlafaxine XR (DRUG), JNJ26489112 (DRUG).
Who is sponsoring clinical trial NCT01114698?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.